BillionToOne

BillionToOne focuses on innovative molecular diagnostics, utilizing their proprietary QCT technology to detect and measure DNA fragments at a single base-pair level. Their key products include the UNITY Screen, a non-invasive prenatal test that identifies fetal risk for aneuploidies and recessive conditions from a maternal blood sample, and the Northstar liquid biopsy assays, which aid in cancer therapy selection and monitoring by analyzing tumor DNA. Their mission is to enhance healthcare accessibility and precision through cutting-edge molecular testing techniques.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Series D21 Jun, 2024
***
***
***
Series C15 Dec, 2022
***
***
***
Series C30 Mar, 2022
***
***
***
Series B15 Jun, 2021
***
***
***
Series A10 Mar, 2020
***
***
***
Series A13 Mar, 2019
***
***
***
Seed15 Sep, 2017
***
***
***

*** - To view the data, please log into your account or create a new one.

Company valuation calculator

To calculate, specify one of the parameters

News related to BillionToOne1

Filter by
Sort by
BillionToOne
Jun 22, 2024 Show on chart

BillionToOne Raises $130M in Series D Funding

Over 500K patients have received BillionToOne tests to date, and the company has grown from $0M to $125M ARR in the last ~4 years. ...

https://www.finsmes.com/2024/06/billiontoone-raises-130m-in-series-d-funding.html

Investors3

Baillie GiffordBaillie Gifford
Y CombinatorY Combinator
Norwest Venture PartnersNorwest Venture Partners

BillionToOne Twitter